A structured patient empowerment programme for primary immunodeficiency significantly improves general and health-related quality of life.

Fasshauer, Maria; Schuermann, Gesine; Gebert, Norbert; von Bernuth, Horst; Goldacker, Sigune; Krueger, Renate; Manzey, Petra; Notheis, Gundula; Ritterbusch, Henrike; Schauer, Uwe; Schulze, Ilka; Umlauf, Volker; Widmann, Steffi; Baumann, Ulrich (2021). A structured patient empowerment programme for primary immunodeficiency significantly improves general and health-related quality of life. Central European journal of immunology, 46(2), pp. 244-249. Termedia Publishing House 10.5114/ceji.2021.107088

[img]
Preview
Text
CEJI-46-44438.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-Share Alike (CC-BY-NC-SA).

Download (276kB) | Preview

Introduction

Primary immunodeficiencies (PIDs) are a heterogeneous group of rare diseases characterized by increased susceptibility to infections and a reduced quality of life (QoL). The influence of a patient empowerment programme for PID (PID-PEP) on general and health-related QoL was assessed in the present study.

Material and methods

PID-PEP is provided by a multidisciplinary team for patients with PID and immunoglobulin G (IgG) replacement therapy during a weekend course to improve patient self-management regarding chronic disease and long-term therapy. Twenty-six adult patients with PID undergoing PID-PEP were recruited. Short Form-36 (SF-36) and the Life Quality Index (LQI) were assessed as generic and disease-specific QoL instruments before as well as 6 months after the programme.

Results

Median visual analogue scale (VAS) values of present health status significantly increased from 68 at baseline to 76 after PID-PEP (p = 0.002). Furthermore, the SF-36 mental component summary (MCS) significantly improved from 36 to 43 following the programme (p = 0.042). Of the eight SF-36 dimensions, vitality (VT) significantly improved (p = 0.025). Median LQI index significantly increased from 77 at baseline to 86 after PID-PEP (p = 0.008). Furthermore, the LQI domains treatment interference (I) and therapy-related problems (II) significantly improved.

Conclusions

Our PID-PEP significantly improved general and health-related QoL. It needs to be evaluated in future studies whether the beneficial effects of PID-PEP are sustained over longer periods of time and whether repeated PID-PEP sessions further improve QoL outcome.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine
04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine > Paediatric Intensive Care

UniBE Contributor:

Umlauf, Volker Nils

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1426-3912

Publisher:

Termedia Publishing House

Language:

English

Submitter:

Anette van Dorland

Date Deposited:

16 Dec 2021 08:00

Last Modified:

05 Dec 2022 15:57

Publisher DOI:

10.5114/ceji.2021.107088

PubMed ID:

34764794

Uncontrolled Keywords:

IgG replacement therapy education programme patient empowerment programme primary immunodeficiency quality of life treatment satisfaction

BORIS DOI:

10.48350/162478

URI:

https://boris.unibe.ch/id/eprint/162478

Actions (login required)

Edit item Edit item
Provide Feedback